Handbook of Drug Interactions

7. Cardiovascular Drugs 289
irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 11:445–453
(1998).
75. Andersson OK and Neldam S. The antihypertensive effect and tolerability of candesartan
cilexetil, a new generation angiotensin II antagonist, in comparison with losartan [see
comments]. Blood Press 7:53–59 (1998).
76. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of
losartan compared with captopril on mortality in patients with symptomatic heart failure:
randomised trial the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–
1587 (2000).
77. Goldberg AI, Dunlay MC, and Sweet CS. Safety and tolerability of losartan potassium, an
angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine
ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic
hypertension. Am J Cardiol 75:793–795 (1995).
78. Faison EP, Snavely DB, Thiyagarajan B, and Nelson EB. The incidence of cough with the
angiotensin II receptor antagonist, losartan, is significantly less than with angiotensin converting
enzyme inhibitors and is similar to that of placebo (abstract). Am J Hypertens 7:
34A (1994).
79. van Rijnsoever EW, Kwee-Zuiderwijk WJ, and Feenstra J. Angioneurotic edema attributed
to the use of losartan. Arch Intern Med 158:2063–2065 (1998).
80. Heeringa M and Van Puijenbroek EP. Reversible dysgeusia attributed to losartan (letter).
Ann Intern Med 129:72 (1998).
81. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, et al. ACE inhibition
or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int
58:2084–2092 (2000).
82. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in
patients with heart failure. N Engl J Med 336(8):525–533 (1997).
83. Lindenbaum J, Maulitz RM, and Butler VP. Inhibition of digoxin absorption by neomycin.
Gastroenterology 71:399–404 (1976).
84. Lindenbaum J, Rund DH, Butler VP Jr, Tse-Eng D, and Saha, JR. Inactivation of digoxin
by the gut flora: reversal by antibiotic therapy. N Engl J Med 305:789–794 (1981).
85. Nademanee K and Kannan R. Amiodarone-digoxin interaction: clinical significance, time
course of development, potential pharmacokinetic mechanisms and therapeutic implications.
J Am Coll Cardiol 4:111–116 (1984).
86. Doering W. Quinidine-digoxin interaction. Pharmacokinetics, underlying mechanism, and
clinical implications. N Engl J Med 301:400–404 (1979).
87. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, et al. Digoxinquinidine
interaction. N Engl J Med 300:1238–1241 (1979).
88. Fromm MF, Kim RB, Stein CM, Wilkinson GR, and Roden DM. Inhibition of P-glycoprotein-mediated
drug transport. A unifying mechanism to explain the interaction between
digoxin and quinidine. Circulation 99:552–557 (1999).
89. Waldorff S, Hansen PB, Egeblad H, Berning J, Buch J, Kjaergard H, et al. Interactions
between digoxin and potassium-sparing diuretics. Clin Pharmacol Ther 33:418–423 (1983).
90. Dorian P, Strauss M, Cardella C, David T, East S, and Ogilvie R. Digoxin-cyclosporine
interaction: severe digitalis toxicity after cyclosporine treatment. Clin Invest Med 11:108–
112 (1988).
91. Leibovitz A, Bilchinsky T, Gil I, and Habot B. Elevated serum digoxin level associated
with coadministered fluoxetine. Arch Intern Med 158:1152–1153 (1998).
92. DePace NL, Herling IH, Kotler ML, Hakki AH, Spielman SR, and Segal BL. Intravenous
nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern
Med 142:1806–1809 (1982).